A Study to Assess the Quinagolide Vaginal Ring for Endometriosis-related Pain

Overview

Información sobre este estudio

The purpose of this study is to evaluate the effectiveness of three doses of quinagolide administered as an extended-release vaginal ring compared to placebo on reduction of moderate-to-severe endometriosis-related pain

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Pre-menopausal females aged ≥ 18 years at time of signing informed consent(s). 
  • Body mass index (BMI) of 18-42 kg/m2 (both inclusive) at screening.
  • Initial confirmation of endometriosis by laparoscopy or laparotomy within the last 10 years before the run-in visit. 
  • Transvaginal ultrasound documenting a uterus with no clinically significant abnormalities and presence of at least one ovary with no clinically significant abnormalities (e.g., no evidence of endometrioma greater than 3 cm in diameter) at the run-in visit.
  • Having moderate to severe endometriosis-related pain. 
  • Willing to use a non-hormonal barrier method (i.e., condom) for contraception from randomization to the end-of-trial. This is not required if adequate contraception is achieved by vasectomy of the sexual partner or surgical sterilization of the subject. 
  • Willing to avoid the use of vaginal douches or any other intravaginally administered medications or devices from randomization to the end of treatment. 
  • Willing to change usual analgesics to rescue analgesics as permitted by protocol for endometriosis-related pain from the start of run-in to the end-of-trial.

Exclusion Criteria:

  • Use of depot medroxyprogesterone acetate (MPA) within 10 months of the start of run-in. 
  • Use of gonadotropin releasing hormone (GnRH) agonists (3 months depot) or dopamine agonists within 6 months of the start of run-in.
  • Use of GnRH agonists (1 month depot) or intrauterine device within 3 months of the start of run-in.
  • Use of GnRH antagonist, combined oral contraceptive pill or progestin-only pill within 1 month of the start of run-in.
  • Undiagnosed abnormal vaginal bleeding.
  • History of no relief of endometriosis related pain after any medical therapy or surgery. However, history of partial pain relief, discontinuation due to side effects are not exclusionary. 
  • Known bone diseases (e.g., osteoporosis, Paget's disease and osteomalacia) affecting bone resorption or bone formation markers. 
  • Any significant abnormal findings of heart examinations before randomization.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Tatnai Burnett, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20468263

Mayo Clinic Footer